GISSI试验开创了溶栓时代,其结果于1985年报道,并在1986年初发表。这项研究在11712例急性心肌梗死患者中评价了链激酶(150万单位,60分钟内静脉滴注)的疗效。与标准治疗相比,在症状出现后12小时内给予链激酶的患者,住院期间总死亡率降低18％,统计学上差别非常显著。这种效益与开始治疗时间的早晚有关,在症状出现后1小时和3小时治疗的患者,住院期间死亡率分别降低47％和23％。该文对参加GISSI研 The GISSI trial pioneered the thrombolytic era, the result of which was reported in 1985 and published in early 1986. The study evaluated the efficacy of streptokinase (1.5 million units, intravenous infusion over a 60-minute period) in 11712 patients with acute myocardial infarction. In patients treated with streptokinase within 12 hours of symptom onset, there was a 18% reduction in overall hospital mortality over the standard treatment, with a statistically significant difference. This benefit is related to the timing of the start of treatment, with in-hospital mortality reduced by 47% and 23%, respectively, at 1 hour and 3 hours after symptom onset. This article participates in GISSI research